Butler/Till

Small audiences aren’t the problem in rare disease marketing. Strategy is.

When brands rely on broad research, late-stage targeting, and surface-level measurement, growth stalls. Not because the audience isn’t there, but because it’s not being found or engaged the right way.

This playbook outlines how to change that. From custom research to earlier patient engagement to measurement built for optimization.

Check out our Rare Disease Media Playbook below for more insights!

💡 http://butlertill-9268363.hs-sites.com/rare-disease-playbook

The first agentic media buying case study is here.

And the results speak for themselves:
- 82% lower supply chain costs
- 40% more impressions
- 30% lower CPMs
- 98% VCR

No trade-offs. Just better performance.

In partnership with PubMatic and our client Geloso Beverage Group, this work reflects what’s possible when innovation is applied with intention.

Read more in Digiday's latest article here:

Butler/Till’s first agentic media buying tests cut media and supply chain costs Initial campaign tests by the indie agency and Pubmatic show cost reductions and time saved. Success, inevitably, brings more questions.